Idiopathic Multicentric Castleman's Disease
1
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
1 companies ranked by most advanced pipeline stage
RecordatiFrance - Saint-Victor
2 programs1
SiltuximabPhase 2Monoclonal Antibody1 trial
Research questionsN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
RecordatiSiltuximab
RecordatiResearch questions
Clinical Trials (2)
Total enrollment: 122 patients across 2 trials
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
Start: Mar 2021Est. completion: Apr 202122 patients
Phase 2Terminated
Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS)
Start: Oct 2023Est. completion: Dec 2024100 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space